# US 2001/0044469 A1 · Methods and pharmaceutical preparations for normalizing blood pressure with (-)-hydroxycitric acid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0044469 A1
- Document ID: US20010044469A1
- Status: Published application
- Kind: A1
- Application number: 09/781,491
- Filed: 2001-02-13
- Published: 2001-11-22
- Earliest claimed: 2000-02-09
- Assignees: Glykon Technologies Group, LLC
- Inventors: Dallas L. Clouatre; James M. Dunn
- Web page: https://patentgrep.com/patent/US20010044469A1

## CPC

- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method whereby the blood pressure metabolism in an individual showing evidence of dysregulation is improved when that person receives an appropriate oral administration of (−)-hydroxycitric acid. The potassium salt of (−)-hydroxycitric acid is a preferred form of the compound, followed by the sodium salt, then by the amide and other derivatives of the acid. The regulation of blood pressure levels over any given period of time may be improved with a controlled release form of (−)-hydroxycitric acid. Controlled release can be used to provide a sustained and modulated amount of the active to the body as desired and therefore regulate the use of the compound as a hypotensive agent.

## Claims

### Claim 1

A method for treating or ameliorating hypertension or high blood pressure in individuals in need thereof which is comprised of administering orally an effective amount of (−)-hydroxycitric acid.

### Claim 2

A method for treating or ameliorating hypertension or high blood pressure by lowering elevated insulin in individuals in need thereof which is comprised of administering orally an effective amount of (−)-hydroxycitric acid.

### Claim 3

A method for treating or ameliorating hypertension or high blood pressure by lowering elevated glucocorticoid levels in individuals in need thereof which is comprised of administering orally an effective amount of (−)-hydroxycitric acid.

### Claim 4 (depends on 1)

The method of claim 1 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the free acid or its lactone.

### Claim 5 (depends on 1)

The method of claim 1 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the alkali metal salts potassium or sodium (−)-hydroxycitrate.

### Claim 6 (depends on 1)

The method of claim 1 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the alkaline earth metal salts calcium or magnesium (−)-hydroxycitrate.

### Claim 7 (depends on 1)

The method of claim 1 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of a mixture the alkali metal salts and/or the alkaline earth metal salts of (−)-hydroxycitrate or some mixture of alkali metal salts and alkaline earth metal salts of (−)-hydroxycitrate or in the form of therapeutically effective amide and/or ester derivatives of(−)-hydroxycitric acid.

### Claim 8 (depends on 1)

The method of claim 1 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount as the free acid, its lactone or as one or more of the salts or other derivatives of the free acid and is delivered in a controlled release form.

### Claim 9 (depends on 2)

The method of claim 2 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the free acid or its lactone.

### Claim 10 (depends on 2)

The method of claim 2 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the alkali metal salts potassium or sodium (−)-hydroxycitrate.

### Claim 11 (depends on 2)

The method of claim 2 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the alkaline earth metal salts calcium or magnesium (−)-hydroxycitrate.

### Claim 12 (depends on 2)

The method of claim 2 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of a mixture the alkali metal salts and/or the alkaline earth metal salts of (−)-hydroxycitrate or some mixture of alkali metal salts and alkaline earth metal salts of (−)-hydroxycitrate or in the form of therapeutically effective amide and/or ester derivatives of (−)-hydroxycitric acid.

### Claim 13 (depends on 2)

The method of claim 2 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount as the free acid, its lactone or as one or more of the salts or other derivatives of the free acid and is delivered in a controlled release form.

### Claim 14 (depends on 3)

The method of claim 3 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the free acid or its lactone.

### Claim 15 (depends on 3)

The method of claim 3 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the alkali metal salts potassium or sodium (−)-hydroxycitrate.

### Claim 16 (depends on 3)

The method of claim 3 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of the alkaline earth metal salts calcium or magnesium (−)-hydroxycitrate.

### Claim 17 (depends on 3)

The method of claim 3 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount of a mixture the alkali metal salts and/or the alkaline earth metal salts of (−)-hydroxycitrate or some mixture of alkali metal salts and alkaline earth metal salts of (−)-hydroxycitrate or in the form of therapeutically effective amide and/or ester derivatives of (−)-hydroxycitric acid.

### Claim 18 (depends on 3)

The method of claim 3 where the (−)-hydroxycitric acid is supplied as a therapeutically effective amount as the free acid, its lactone or as one or more of the salts or other derivatives of the free acid and is delivered in a controlled release form.
